Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Acute lymphoblastic leukemia

Acute lymphoblastic leukemia and down syndrome: 6-mercaptopurine and methotrexate metabolites during maintenance therapy

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: Dynamics in 6MP/MTX metabolites during maintenance therapy of childhood acute lymphoblastic leukemia, data from children with (DS) and without Down syndrome (non–DS).


  1. 1.

    Hasle H. Pattern of malignant disorders in individuals with Down’s syndrome. Lancet Oncol. 2001;2:429–36.

    CAS  Article  Google Scholar 

  2. 2.

    Lee P, Bhansali R, Izraeli S, Hijiya N, Crispino JD. The biology, pathogenesis and clinical aspects of acute lymphoblastic leukemia in children with Down syndrome. Leukemia. 2016;30:1816–23.

    CAS  Article  Google Scholar 

  3. 3.

    Maloney KW, Carroll WL, Carroll AJ, Devidas M, Borowitz MJ, Martin PL, et al. Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children’s Oncology Group. Blood. 2010;116:1045–50.

    CAS  Article  Google Scholar 

  4. 4.

    Buitenkamp TD, Izraeli S, Zimmermann M, Forestier E, Heerema NA, van den Heuvel-Eibrink MM, et al. Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group. Blood. 2014;123:70–7.

    CAS  Article  Google Scholar 

  5. 5.

    Bohnstedt C, Levinsen M, Rosthøj S, Zeller B, Taskinen M, Hafsteinsdottir S, et al. Physicians compliance during maintenance therapy in children with Down syndrome and acute lymphoblastic leukemia. Leukemia. 2013;27:866–70.

    CAS  Article  Google Scholar 

  6. 6.

    Schmiegelow K, Nielsen SN, Frandsen TL, Nersting J. Mercaptopurine/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction. J Pediatr Hematol Oncol. 2014;36:503–17.

    CAS  Article  Google Scholar 

  7. 7.

    Lafolie P, Hayder S, Björk O, Ahström L, Liliemark J, Peterson C. Large interindividual variations in the pharmacokinetics of oral 6-mercaptopurine in maintenance therapy of children with acute leukaemia and non-Hodgkin lymphoma. Acta Paediatr Scand. 1986;75:797–803.

    CAS  Article  Google Scholar 

  8. 8.

    Hedeland RL, Hvidt K, Nersting J, Rosthøj S, Dalhoff K, Lausen B, et al. DNA incorporation of 6-thioguanine nucleotides during maintenance therapy of childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma. Cancer Chemother Pharm. 2010;66:485–91.

    CAS  Article  Google Scholar 

  9. 9.

    Nielsen SN, Grell K, Nersting J, Abrahamsson J, Lund B, Kanerva J, et al. DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial. Lancet Oncol. 2017;18:515–24.

    CAS  Article  Google Scholar 

  10. 10.

    Mikkelsen TS, Thorn CF, Yang JJ, Ulrich CM, French D, Zaza G, et al. PharmGKB summary. Pharmacogenet Genomics. 2011;21:679–86.

    CAS  Article  Google Scholar 

  11. 11.

    Chabner BA, Allegra CJ, Curt GA, Clendeninn NJ, Baram J, Koizumi S, et al. Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest. 1985;76:907–12.

    CAS  Article  Google Scholar 

  12. 12.

    Taub JW, Ge Y. Down syndrome, drug metabolism and chromosome 21. Pediatr Blood Cancer. 2005;44:33–9.

    Article  Google Scholar 

  13. 13.

    Gregers J, Christensen IJ, Dalhoff K, Lausen B, Schroeder H, Rosthoej S, et al. The association of reduced folate carrier 80G>A polymorphism to outcome in childhood acute lymphoblastic leukemia interacts with chromosome 21 copy number. Blood. 2010;115:4671–7.

    CAS  Article  Google Scholar 

  14. 14.

    Toft N, Birgens H, Abrahamsson J, Griškevičius L, Hallböök H, Heyman M, et al. Results of NOPHO ALL2008 treatment for patients aged 1–45 years with acute lymphoblastic leukemia. Leukemia. 2018;32:606–15.

    CAS  Article  Google Scholar 

  15. 15.

    Roberts I, Izraeli S. Haematopoietic development and leukaemia in Down syndrome. Br J Haematol. 2014;167:587–99.

    CAS  Article  Google Scholar 

Download references


This study has received financial support from: The Danish Cancer Society (Grant nos: 91-048, 92-017, 93-017, 95-100-28, R19-A984, R214-A12962), The Otto Christensen Foundation, The Swedish Childhood Cancer Foundation (Grant nos. 53/91, 62/94, 72/96, 98/59), The Lundbeck Foundation (Grant no. 38/99) and The Danish Childhood Cancer Foundation. Thanks to the Nordic Society of Pediatric Hematology and Oncology for their participation in this study.

Author information





AØ collected data, analyzed data and drafted the paper; CB designed the study, collected data and drafted the paper; KG analyzed data and drafted the paper; MD and PH drafted the paper; BZ, MT, SH, HB and MH collected data; KS is chair of the NOPHO ALL2008 protocol, designed the study, collected data and drafted the paper.

Corresponding author

Correspondence to Kjeld Schmiegelow.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Østergaard, A., Bohnstedt, C., Grell, K. et al. Acute lymphoblastic leukemia and down syndrome: 6-mercaptopurine and methotrexate metabolites during maintenance therapy. Leukemia 35, 863–866 (2021).

Download citation


Quick links